HER2 Support Group Forums - View Single Post - a new kind of her2neu +er= breast cancer type--baso-luminal!

Christine MH-UK · 08-16-2006, 09:20 AM

Unfortunately, they are a rather different four:

From Harold J. Burstein, The Distinctive Nature of Her2-Positive Breast Cancers:

Hormone receptors, HER2, and increasingly, genomic profiles distinguish at least four major classes of breast cancer: HER2-positive tumors; HER2-negative, hormonereceptor–positive tumors, which can be divided into two classes, favorable and unfavorable, on the basis of genomic and pathobiologic features; and basal-like tumors that express neither HER2 nor hormone receptors.

I am not sure what the fifth type would be, although I remember some postings suggesting that slightly her2 cancers were perhaps another subtype.

Another four possibilities come from the "Defeat Cancer" project website:
http://www.worldcommunitygrid.org/pr...HdcResearch.do

Subclasses of Cancer
"Within broad categories of cancer – such as breast, liver, or lung, there are subclasses of cancer. Breast cancer, for example, is a broad category that consists of a number of subclasses (including intraductal, lobular, medullary, colloid), which exhibit variation in terms of aggressiveness and which require specific treatments and drug regimens. So rather than looking at breast cancer as a single disease, doctors must treat it as a multitude of diseases, each requiring targeted therapies."

I suspect that the five types are just a start anyway. Part of the purpose of the Help Defeat Cancer project is to figure out the genetic commonalities that distinguish different cancer subtypes and what existing treatments have been most effective (similar to the recent finding that FEC is much better than CMF for her2positive breast cancer). The project is relying on donated computer time to analyze hundreds of thousands of breast cancer and head and neck cancer samples over the next three months and the hope is that this will enable the faster development of better targeted therapies.

The only disappointing thing about the project is that it requires 750MB of RAM to participate in the cancer project, although there are also less memory intensive biomedical projects running on the World Community Grid involving folding proteins relevant to disease and screening potential AIDS drugs. All of the knowledge developed remains in the public domain.

08-16-2006, 09:20 AM	#2
Christine MH-UK Senior Member Join Date: Sep 2005 Posts: 414	Two sources provide four Unfortunately, they are a rather different four: From Harold J. Burstein, The Distinctive Nature of Her2-Positive Breast Cancers: Hormone receptors, HER2, and increasingly, genomic profiles distinguish at least four major classes of breast cancer: HER2-positive tumors; HER2-negative, hormonereceptor–positive tumors, which can be divided into two classes, favorable and unfavorable, on the basis of genomic and pathobiologic features; and basal-like tumors that express neither HER2 nor hormone receptors. I am not sure what the fifth type would be, although I remember some postings suggesting that slightly her2 cancers were perhaps another subtype. Another four possibilities come from the "Defeat Cancer" project website: http://www.worldcommunitygrid.org/pr...HdcResearch.do Subclasses of Cancer "Within broad categories of cancer – such as breast, liver, or lung, there are subclasses of cancer. Breast cancer, for example, is a broad category that consists of a number of subclasses (including intraductal, lobular, medullary, colloid), which exhibit variation in terms of aggressiveness and which require specific treatments and drug regimens. So rather than looking at breast cancer as a single disease, doctors must treat it as a multitude of diseases, each requiring targeted therapies." I suspect that the five types are just a start anyway. Part of the purpose of the Help Defeat Cancer project is to figure out the genetic commonalities that distinguish different cancer subtypes and what existing treatments have been most effective (similar to the recent finding that FEC is much better than CMF for her2positive breast cancer). The project is relying on donated computer time to analyze hundreds of thousands of breast cancer and head and neck cancer samples over the next three months and the hope is that this will enable the faster development of better targeted therapies. The only disappointing thing about the project is that it requires 750MB of RAM to participate in the cancer project, although there are also less memory intensive biomedical projects running on the World Community Grid involving folding proteins relevant to disease and screening potential AIDS drugs. All of the knowledge developed remains in the public domain.